StageZero Life Sciences: The World’s 1st Multi-cancer Test

Positioned for significant growth

StageZero Life Sciences is focused on the early detection of multiple diseases through whole blood tests. Its next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer.

Further, StageZero’s full service, telehealth platform includes access to physicians and phlebotomists. They can prescribe and draw samples for individuals and groups. The company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). Moreover, its recent partnerships have positioned StageZero for significant growth.

For more information on StageZero Life Sciences, Ltd. (TSX: SZLS) please click on the request investor info button.